Hyundai BioLand Co Ltd
KOSDAQ:052260
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Hyundai BioLand Co Ltd
Gross Profit
Hyundai BioLand Co Ltd
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hyundai BioLand Co Ltd
KOSDAQ:052260
|
Gross Profit
₩53.5B
|
CAGR 3-Years
15%
|
CAGR 5-Years
25%
|
CAGR 10-Years
5%
|
|
|
AmorePacific Corp
KRX:090430
|
Gross Profit
₩3.1T
|
CAGR 3-Years
3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-2%
|
|
|
Amorepacific Group
KRX:002790
|
Gross Profit
₩3.4T
|
CAGR 3-Years
3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-2%
|
|
|
Cosmax Inc
KRX:192820
|
Gross Profit
₩409B
|
CAGR 3-Years
26%
|
CAGR 5-Years
14%
|
CAGR 10-Years
17%
|
|
|
LG H&H Co Ltd
KRX:051900
|
Gross Profit
₩3.1T
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
0%
|
|
|
Kolmar Korea Co Ltd
KRX:161890
|
Gross Profit
₩791.4B
|
CAGR 3-Years
19%
|
CAGR 5-Years
13%
|
CAGR 10-Years
20%
|
|
Hyundai BioLand Co Ltd
Glance View
HYUNDAI BIOLAND Co., Ltd. engages in the manufacture and sale of pharmaceutical and functional products. The company is headquartered in Cheongju, Chungcheongbuk-Do. The company went IPO on 2001-05-17. The firm operates its business through four segments. The Cosmetic Raw Material segment produces products such as portulaca extracts, ulmus extracts, crinum extracts, hyaluronic acids and arbutins. The Pharmaceutical Ingredient segment manufactures and sells products such as phellodendron extracts, ampelopsis extracts and gardenia extracts and others. The Ingredients for Health Functional Food segment produces and distributes red ginseng extract powders, seaweed powders, glucosamine powders, black garlic extract powders, dandelion extract powders, green tea extracts and others. The Medical Device segment involves in the provision of medical equipment such as tissue engineering products, comprised of biological wound dressings and collagen, as well as diagnostic kits, comprised of rapid kits, serological kits and mask packs.
See Also
What is Hyundai BioLand Co Ltd's Gross Profit?
Gross Profit
53.5B
KRW
Based on the financial report for Dec 31, 2025, Hyundai BioLand Co Ltd's Gross Profit amounts to 53.5B KRW.
What is Hyundai BioLand Co Ltd's Gross Profit growth rate?
Gross Profit CAGR 10Y
5%
Over the last year, the Gross Profit growth was 1%. The average annual Gross Profit growth rates for Hyundai BioLand Co Ltd have been 15% over the past three years , 25% over the past five years , and 5% over the past ten years .
